Company intelligence / Profile preview

IONTAS

Sawston, Cambridgeshire, United Kingdom

Ownership: Private
Employees: ~25
Development stage: Other

Overview

IONTAS contributes proprietary antibody components for biologics in clinical development (e.g., FS222, a CD137/PD-L1 bispecific in Phase 1 oncology trials with F-star Therapeutics) and supports partner programs through discovery to optimization; it is not a traditional product-based biotech but a platform company with partners advancing clinical candidates[3].

Therapeutic areas: OncologyInfectious DiseasesImmunology
Modalities: AntibodyBispecific monoclonal antibodyRecombinant protein
Industry: Drug Discovery Services

Partnerships

Teva PharmaceuticalsF-star TherapeuticsQuell TherapeuticsInotremargenxFairJourney Biologics

Beyond the preview

Go deeper on IONTAS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IONTAS.

Explore the full profile